![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 6
Zeitschriftenartikel
Fischer, Laura E. 
ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
Stahler, Arndt; Stintzing, Sebastian; Modest, Dominik P.; Ricard, Ingrid; Giessen-Jung, Clemens; Kapaun, Christine; Ivanova, Boryana; Kaiser, Florian; Fischer von Weikersthal, Ludwig; Moosmann, Nicolas; Schalhorn, Andreas; Stauch, Martina; Kiani, Alexander; Held, Swantje; Decker, Thomas; Moehler, Markus; Neumann, Jens; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2020):
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials.
In: Clinical Cancer Research, Bd. 26, Nr. 24: S. 6559-6567
Stahler, Arndt; Heinemann, Volker; Neumann, Jens; Crispin, Alexander; Schalhorn, Andreas; Stintzing, Sebastian; Giessen-Jung, Clemens; Fischer von Weikersthal, Ludwig; Vehling-Kaiser, Ursula; Stauch, Martina; Quietzsch, Detlef; Holch, Julian W.; Kruger, Stephan; Haas, Michael; Michl, Marlies; Einem, Jobst von; Kirchner, Thomas; Jung, Andreas und Modest, Dominik P.
(2017):
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
In: Anti-cancer drugs, Bd. 28, Nr. 7: S. 717-722
[PDF, 422kB]
Modest, Dominik P.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Scheithauer, Werner; Kirchner, Thomas; Jung, Andreas; Stauch, Martina; Einem, Jobst Christian von; Möhler, Markus; Held, Swantje und Heinemann, Volker
(2017):
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
In: International Journal of Cancer, Bd. 140, Nr. 8: S. 1918-1925
Modest, Dominik Paul; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Sobrero, Alberto F.; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Seipelt, Gernot; Lerchenmüller, Christian A.; Kahl, Christoph; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Moehler, Markus H.; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2016):
Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab).
In: Journal of Clinical Oncology, Bd. 34, Nr. 4
Stintzing, Sebastian; Modest, Dominik P.; Rossius, Lisa; Lerch, Markus M.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Giessen-Jung, Clemens; Moehler, Markus; Jagenburg, Andreas; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2016):
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
In: Lancet Oncology, Bd. 17, Nr. 10: S. 1426-1434